Diabetes mellitus and other underlying conditions in patients with coronavirus disease 2019 associated rhino-orbito-cerebral mucormycosis: a systematic review and meta-analysis

Abstract

Objective This study aimed to compute the pooled prevalence of diabetes mellitus and other underlying conditions in patients with coronavirus disease 2019 associated rhino-orbito-cerebral mucormycosis. Method A systematic literature review was performed in PubMed, Scopus, Web of Science, Embase and Google Scholar. The cross-sectional studies that reported the frequency of diabetes mellitus in patients with coronavirus disease 2019 associated rhino-orbito-cerebral mucormycosis were included. Results Eighteen eligible studies with a total number of 3718 patients were included in the current study. The pooled prevalence of diabetes in patients with coronavirus disease 2019 associated rhino-orbito-cerebral mucormycosis was 89 per cent and with new-onset diabetes was 32 per cent. The pooled prevalence of steroid use was high (79 per cent) too. The all-cause mortality rate was 24 per cent. Conclusion Diabetes mellitus was the most frequent underlying condition in patients with coronavirus disease 2019 associated rhino-orbito-cerebral mucormycosis. The second most frequent underlying condition was steroid use during coronavirus disease 2019 infection. The appropriate control of hyperglycaemia and rational prescription of steroids during the treatment of coronavirus disease 2019 associated rhino-orbito-cerebral mucormycosis is recommended.

Exploring Prevalence Trends of Jaw Bone Pathologies: A Three-Year Institutional Study

“…Secondly, corticosteroids can elevate blood glucose levels, exacerbating glycemic control in diabetic patients. Moreover, in countries like India, where corticosteroids are available over the counter, improper and prolonged steroid use might heighten susceptibility to mucormycosis [ 13 , 14 ].…”

“…Individuals with COVID-19 may experience alterations in immune function, including impaired inflammatory responses and compromised immune surveillance. These changes could potentially exacerbate existing inflammatory conditions [ 14 ].…”

Short intravenous amphotericin B followed by oral posaconazole using a simple, stratified treatment approach for diabetes or COVID-19-associated rhino-orbito-cerebral mucormycosis: a prospective cohort study

“…Several novel observations have emerged on studies reporting on COVID 19 associated mucormycosis. Firstly, in many reports the mortality associated with COVID 19, appears to be lower than mucormycosis with other risk factors [ [10] , [11] , [12] ]. Few meta-analyses report a lower proportion of CNS involvement among COVID-19 associated mucormycosis, but not others [ 10 ].…”

“…Firstly, in many reports the mortality associated with COVID 19, appears to be lower than mucormycosis with other risk factors [ [10] , [11] , [12] ]. Few meta-analyses report a lower proportion of CNS involvement among COVID-19 associated mucormycosis, but not others [ 10 ]. There is also increased awareness and earlier presentation to the hospital setting.…”